LLY - Eli Lilly to acquire Point Biopharma in $1.4B deal
2023-10-03 07:17:09 ET
More on POINT Biopharma
- POINT Biopharma: Leading The Future Of Radioligand Therapy
- POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials
- POINT Biopharma slips after pipeline update
- Seeking Alpha’s Quant Rating on POINT Biopharma Global
- Historical earnings data for POINT Biopharma Global
For further details see:
Eli Lilly to acquire Point Biopharma in $1.4B deal